Please login to the form below

Not currently logged in
Email:
Password:

anti-NGF

This page shows the latest anti-NGF news and features for those working in and with pharma, biotech and healthcare.

FDA halts study of Teva and Regeneron's pain drug fasinumab

FDA halts study of Teva and Regeneron's pain drug fasinumab

Arthropathy has been seen before with NGF inhibitors - and caused the agency to put the entire class under a clinical hold in 2011. ... Eli Lilly and partner Pfizer also remain in the race with their tanezumab anti-NGF candidate, which restarted testing

Latest news

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    That hold was subsequently relaxed to a partial hold, allowing some drugmakers to resume testing and leading to optimism that anti-NGF programmes may get back on track. ... The decision was attributed to shifting commercial priorities rather than a

  • Lilly eyes pivotal trials for pain drug tanezumab in 2015 Lilly eyes pivotal trials for pain drug tanezumab in 2015

    The antibody drug targets nerve growth factor (NGF) and - if approved - would represent a completely new drug class for chronic pain conditions, including osteoarthritis and cancer-related pain. ... In 2012 however a new partial clinical hold on the

  • J&J chief predicts 10 new pharma filings by 2017 J&J chief predicts 10 new pharma filings by 2017

    Among the pipeline projects highlighted by Gorsky are esketamine, a glutamate NMDA antagonist that he described as a "potential breakthrough medication" for treatment-resistant depression, as well as anti-CD38 antibody ... Fulranumab, an anti-nerve

  • Pfizer sales down but oncology shows promise Pfizer sales down but oncology shows promise

    There were also gains for anti-inflammatory Celebrex (celecoxib), up 11 per cent to $752m, while fibromyalgia drug Lyrica (pregabalin) cemented its position as Pfizer's biggest-selling product with a ... The company has also joined forces with Lilly to

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics